Daunorubicin (Daunomycin) hydrochloride 是一种拓扑异构酶 II (topoisomerase II) 抑制剂，具有有效的抗肿瘤活性。Daunorubicin hydrochloride 抑制 DNA 和 RNA 合成 (DNA and RNA synthesis)。Daunorubicin hydrochloride 是一种细胞毒素，可抑制癌细胞活力并诱导细胞凋亡 (apoptosis) 和坏死 (necrosis)。Daunorubicin hydrochloride 还是一种蒽环类抗生素。Daunorubicin hydrochloride 可用于研究感染和多种癌症，包括白血病、非霍奇金淋巴瘤、尤文氏肉瘤、维尔姆斯氏瘤。
| 生物活性 | Daunorubicin (Daunomycin) hydrochloride is atopoisomeraseIIinhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibitsDNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibitscancercell viability and inducesapoptosisandnecrosis. Daunorubicin hydrochloride is also an anthracyclineantibiotic. Daunorubicin hydrochloride can be used in the research ofinfectionand variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5]. |
| IC50& Target[1][2] | Topoisomerase II | Daunorubicins/Doxorubicins |
|
体外研究
(In Vitro) | Daunorubicin hydrochloride (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells[2].
Daunorubicin hydrochloride (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells[3][4].
Daunorubicin hydrochloride (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells[4].
Daunorubicin hydrochloride (0.4 μM, 120 min) induces ROS generation in L3.6 cells[4].
Daunorubicin hydrochloride (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line)[6].
Cell Viability Assay[3][4] | Cell Line: | Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line) | | Concentration: | 7 nM-1.9 μM | | Incubation Time: | 72 h | | Result: | Inhibited cell viability with IC50values of 40 nM (Molt-4) and 400 nM (L3.6). |
Apoptosis Analysis[4] | Cell Line: | L3.6 cells | | Concentration: | 0.4 μM | | Incubation Time: | 72 h | | Result: | Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h. |
Western Blot Analysis[6]: | Cell Line: | K562 cells | | Concentration: | 2 μM | | Incubation Time: | 24 h | | Result: | Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3. |
|
体内研究
(In Vivo) | Daunorubicin hydrochloride (intravenous injection, 3 mg/kg, three times at 48 h intervals.) produces cardiotoxicity and nephrotoxicity in rats[5].
Daunorubicin hydrochloride (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice[7].
| Animal Model: | Male Sprague-Dawley rats[5] | | Dosage: | 3 mg/kg | | Administration: | Intravenous injection, three times at 48 h intervals. | | Result: | Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity.
Increased urinary protein excretion, serum creatinine, and BUN level. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | 盐酸柔红霉素；盐酸佐柔比星；道诺霉素盐酸盐；盐酸正定霉素；盐酸红比霉素 |
| 结构分类 | |
| 来源 | Streptomyces coeruleorubidus |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| 溶解性数据 | In Vitro: DMSO : 50 mg/mL(88.66 mM;Need ultrasonic) H2O : ≥ 34 mg/mL(60.29 mM) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 1.7731 mL | 8.8656 mL | 17.7311 mL | | 5 mM | 0.3546 mL | 1.7731 mL | 3.5462 mL | | 10 mM | 0.1773 mL | 0.8866 mL | 1.7731 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 33.33 mg/mL (59.10 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.69 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.69 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
